LCD UncertaintyORGO's 1Q25 results were negatively impacted by continued LCD uncertainty regarding skin substitute grafts, where implementation has been delayed a third time to January 1, 2026.
Sales GuidanceManagement's revised sales guidance implies a significant back-end weighted ramp, which in our view adds a degree of risk in hitting full year targets.
Sales RisksDespite good performance, LCDs and sales risks remain an overhang on shares, potentially limiting stock value growth.